Cargando…
CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896602/ https://www.ncbi.nlm.nih.gov/pubmed/23995618 http://dx.doi.org/10.4161/mabs.26201 |
_version_ | 1782300102001426432 |
---|---|
author | Fennell, Brian J McDonnell, Barry Tam, Amy Sze Pui Chang, Lijun Steven, John Broadbent, Ian D Gao, Huilan Kieras, Elizabeth Alley, Jennifer Luxenberg, Deborah Edmonds, Jason Fitz, Lori J Miao, Wenyan Whitters, Matthew J Medley, Quintus G Guo, Yongjing J Darmanin-Sheehan, Alfredo Autin, Bénédicte Shúilleabháin, Deirdre Ní Cummins, Emma King, Amy Krebs, Mark RH Grace, Christopher Hickling, Timothy P Boisvert, Angela Zhong, Xiaotian McKenna, Matthew Francis, Christopher Olland, Stephane Bloom, Laird Paulsen, Janet Somers, Will Jensen, Allan Lin, Laura Finlay, William JJ Cunningham, Orla |
author_facet | Fennell, Brian J McDonnell, Barry Tam, Amy Sze Pui Chang, Lijun Steven, John Broadbent, Ian D Gao, Huilan Kieras, Elizabeth Alley, Jennifer Luxenberg, Deborah Edmonds, Jason Fitz, Lori J Miao, Wenyan Whitters, Matthew J Medley, Quintus G Guo, Yongjing J Darmanin-Sheehan, Alfredo Autin, Bénédicte Shúilleabháin, Deirdre Ní Cummins, Emma King, Amy Krebs, Mark RH Grace, Christopher Hickling, Timothy P Boisvert, Angela Zhong, Xiaotian McKenna, Matthew Francis, Christopher Olland, Stephane Bloom, Laird Paulsen, Janet Somers, Will Jensen, Allan Lin, Laura Finlay, William JJ Cunningham, Orla |
author_sort | Fennell, Brian J |
collection | PubMed |
description | While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for high-concentration, stable formulations that allow subcutaneous delivery. Our aim was to generate a tetravalent bispecific molecule targeting two inflammatory mediators for synergistic immune modulation. We focused on an scFv-Fc-scFv format, with a flexible (A(4)T)(3) linker coupling an additional scFv to the C-terminus of an scFv-Fc. While one of the lead scFvs isolated directly from a naïve library was well-behaved and sufficiently potent, the parental anti-CXCL13 scFv 3B4 required optimization for affinity, stability, and cynomolgus ortholog cross-reactivity. To achieve this, we eschewed framework-based stabilizing mutations in favor of complementarity-determining region (CDR) mutagenesis and re-selection for simultaneous improvements in both affinity and thermal stability. Phage-displayed 3B4 CDR-mutant libraries were used in an aggressive “hammer-hug” selection strategy that incorporated thermal challenge, functional, and biophysical screening. This approach identified leads with improved stability and >18-fold, and 4,100-fold higher affinity for both human and cynomolgus CXCL13, respectively. Improvements were exclusively mediated through only 4 mutations in V(L)-CDR3. Lead scFvs were reformatted into scFv-Fc-scFvs and their biophysical properties ranked. Our final candidate could be formulated in a standard biopharmaceutical platform buffer at 100 mg/ml with <2% high molecular weight species present after 7 weeks at 4 °C and viscosity <15 cP. This workflow has facilitated the identification of a truly manufacturable scFv-based bispecific therapeutic suitable for subcutaneous administration. |
format | Online Article Text |
id | pubmed-3896602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-38966022014-01-29 CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery Fennell, Brian J McDonnell, Barry Tam, Amy Sze Pui Chang, Lijun Steven, John Broadbent, Ian D Gao, Huilan Kieras, Elizabeth Alley, Jennifer Luxenberg, Deborah Edmonds, Jason Fitz, Lori J Miao, Wenyan Whitters, Matthew J Medley, Quintus G Guo, Yongjing J Darmanin-Sheehan, Alfredo Autin, Bénédicte Shúilleabháin, Deirdre Ní Cummins, Emma King, Amy Krebs, Mark RH Grace, Christopher Hickling, Timothy P Boisvert, Angela Zhong, Xiaotian McKenna, Matthew Francis, Christopher Olland, Stephane Bloom, Laird Paulsen, Janet Somers, Will Jensen, Allan Lin, Laura Finlay, William JJ Cunningham, Orla MAbs Report While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for high-concentration, stable formulations that allow subcutaneous delivery. Our aim was to generate a tetravalent bispecific molecule targeting two inflammatory mediators for synergistic immune modulation. We focused on an scFv-Fc-scFv format, with a flexible (A(4)T)(3) linker coupling an additional scFv to the C-terminus of an scFv-Fc. While one of the lead scFvs isolated directly from a naïve library was well-behaved and sufficiently potent, the parental anti-CXCL13 scFv 3B4 required optimization for affinity, stability, and cynomolgus ortholog cross-reactivity. To achieve this, we eschewed framework-based stabilizing mutations in favor of complementarity-determining region (CDR) mutagenesis and re-selection for simultaneous improvements in both affinity and thermal stability. Phage-displayed 3B4 CDR-mutant libraries were used in an aggressive “hammer-hug” selection strategy that incorporated thermal challenge, functional, and biophysical screening. This approach identified leads with improved stability and >18-fold, and 4,100-fold higher affinity for both human and cynomolgus CXCL13, respectively. Improvements were exclusively mediated through only 4 mutations in V(L)-CDR3. Lead scFvs were reformatted into scFv-Fc-scFvs and their biophysical properties ranked. Our final candidate could be formulated in a standard biopharmaceutical platform buffer at 100 mg/ml with <2% high molecular weight species present after 7 weeks at 4 °C and viscosity <15 cP. This workflow has facilitated the identification of a truly manufacturable scFv-based bispecific therapeutic suitable for subcutaneous administration. Landes Bioscience 2013-11-01 2013-08-21 /pmc/articles/PMC3896602/ /pubmed/23995618 http://dx.doi.org/10.4161/mabs.26201 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Report Fennell, Brian J McDonnell, Barry Tam, Amy Sze Pui Chang, Lijun Steven, John Broadbent, Ian D Gao, Huilan Kieras, Elizabeth Alley, Jennifer Luxenberg, Deborah Edmonds, Jason Fitz, Lori J Miao, Wenyan Whitters, Matthew J Medley, Quintus G Guo, Yongjing J Darmanin-Sheehan, Alfredo Autin, Bénédicte Shúilleabháin, Deirdre Ní Cummins, Emma King, Amy Krebs, Mark RH Grace, Christopher Hickling, Timothy P Boisvert, Angela Zhong, Xiaotian McKenna, Matthew Francis, Christopher Olland, Stephane Bloom, Laird Paulsen, Janet Somers, Will Jensen, Allan Lin, Laura Finlay, William JJ Cunningham, Orla CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
title | CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
title_full | CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
title_fullStr | CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
title_full_unstemmed | CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
title_short | CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
title_sort | cdr-restricted engineering of native human scfvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896602/ https://www.ncbi.nlm.nih.gov/pubmed/23995618 http://dx.doi.org/10.4161/mabs.26201 |
work_keys_str_mv | AT fennellbrianj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT mcdonnellbarry cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT tamamyszepui cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT changlijun cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT stevenjohn cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT broadbentiand cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT gaohuilan cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT kieraselizabeth cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT alleyjennifer cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT luxenbergdeborah cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT edmondsjason cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT fitzlorij cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT miaowenyan cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT whittersmatthewj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT medleyquintusg cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT guoyongjingj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT darmaninsheehanalfredo cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT autinbenedicte cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT shuilleabhaindeirdreni cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT cumminsemma cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT kingamy cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT krebsmarkrh cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT gracechristopher cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT hicklingtimothyp cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT boisvertangela cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT zhongxiaotian cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT mckennamatthew cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT francischristopher cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT ollandstephane cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT bloomlaird cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT paulsenjanet cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT somerswill cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT jensenallan cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT linlaura cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT finlaywilliamjj cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery AT cunninghamorla cdrrestrictedengineeringofnativehumanscfvscreateshighlystableandsolublebifunctionalantibodiesforsubcutaneousdelivery |